Individuals carrying a pathogenic variant for a dominantly inherited arrhythmia have a 50% likelihood of passing the variant on to their children, placing them at higher risk of developing the potentially life-threatening condition (1).
Today, there are a several commercially available sequencing options for genetic testing of inherited arrhythmias, ranging from targeted panels (5-20 genes) to broad pan-arrhythmia panels (170+ genes) and whole exome sequencing (20,000+ genes). While more comprehensive tests increase the sensitivity of variant detection, they also increase the detection of variants of unknown clinical significance, enhancing the complexity of interpretation.